Evidence map›Paper›PMID 38668812›Full record

ArticlePharmacological reports : PR2024

Role of the β

Ehtesham Arif, Ashish K Solanki, Bushra Rahman, Bethany Wolf, Rick G Schnellmann, Deepak Nihalani, Joshua H Lipschutz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological reports : PR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. βBiochemistry research international · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ehtesham ArifDepartment of Medicine, Nephrology Division, Medical University of South Carolina, Clinical Science Building 822N, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA.
Ashish K SolankiDepartment of Medicine, Nephrology Division, Medical University of South Carolina, Clinical Science Building 822N, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA.
Bushra RahmanDepartment of Medicine, Nephrology Division, Medical University of South Carolina, Clinical Science Building 822N, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA.
Bethany WolfDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Rick G SchnellmannDepartment of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, USA.
Deepak Nihalani *Department of Medicine, Nephrology Division, Medical University of South Carolina, Clinical Science Building 822N, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA.
Joshua H Lipschutz *Department of Medicine, Nephrology Division, Medical University of South Carolina, Clinical Science Building 822N, 96 Jonathan Lucas Street, Charleston, SC, 29425, USA. Lipschut@musc.edu.

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7M
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7M
UAB Recessive PKD Research and Translational Core CenterP30DK074038 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YODER, BRADLEY K. · 2005 to 2019
$16.6M
Myo1c Participates in Podocyte Junction Formation Through Interaction with Neph1R01DK087956 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI NIHALANI, DEEPAK · 2010 to 2018
$3.5M
Mitochondrial Biogenesis Promotes Recovery From Oxidant InjuryR01GM084147 · NIGMS · UNIVERSITY OF ARIZONA · PI SCHNELLMANN, RICK G · 2008 to 2016
$2.4M
Confocal/Multiphoton Microscope UpgradeS10OD018113 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LEMASTERS, JOHN J · 2015 to 2015
$570k
Preclinical therapeutic validation of a novel therapeutic lead for treating glomerular diseases such as focal and segmental glomerulosclerosisR56DK116887 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI NIHALANI, DEEPAK, SCHNELLMANN, RICK G · 2018 to 2018
$100k
5-HT Stimulation of Mitochondrial Biogenesis and Acute Kidney InjuryI01BX000851 · VA · SOUTHERN ARIZONA VA HEALTH CARE SYSTEM · PI SCHNELLMANN, RICK G · 2011 to 2025
–
BLRD VA I01 BX000820BLRD VA I01 BX000851CSRD VA I01 CX002391Dialysis Clinics No numberNCI NIH HHS P30 CA138313NIDDK NIH HHS P30 DK074038NIDDK NIH HHS P30DK074038NIDDK NIH HHS R01 DK087956NIDDK NIH HHS R01DK087956NIDDK NIH HHS R56 DK116887NIDDK NIH HHS R56DK116887NIEHS NIH HHS P30 ES006694NIGMS NIH HHS GM084147NIGMS NIH HHS R01 GM084147NIH HHS S10 OD018113U.S. Department of Veterans Affairs BX000851U.S. Department of Veterans Affairs I01BX000820U.S. Department of Veterans Affairs I01CX002391
6 · The paper itself

Abstract

backgroundPodocytes have a remarkable ability to recover from injury; however, little is known about the recovery mechanisms involved in this process. We recently showed that formoterol, a long-acting β

methodsWe genetically deleted the β

resultsA similar level of injury was observed in β

conclusionsThese results indicate that the podocyte β

Indexed as

DoxorubicinFormoterol FumarateMice, KnockoutPodocytesReceptors, Adrenergic, beta-2Acute Kidney InjuryAdrenergic beta-2 Receptor AgonistsAlbuminuriaAnimalsMiceMice, Inbred C57BLAdrenergic beta-2 Receptor AgonistsDoxorubicinFormoterol FumarateReceptors, Adrenergic, beta-2Acute kidney injuryFormoterolβ2-adrenergic receptor

Identifiers

PMID38668812
PMCPMC11126448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.